Middle East Diagnostic Reagents Infectious Diseases Market Report: Market Size & Forecast 2026

The market comprises reagents used in immunoassays, molecular diagnostics, and microbiology testing for infectious disease detection across hospitals, clinical laboratories, and point-of-care settings in the Middle East and Africa region. These reagents are critical components enabling the accurate identification of bacterial, viral, fungal, and parasitic infections that remain significant public health challenges in the region. The market benefits from expanding healthcare access and the transition toward more sophisticated diagnostic platforms that require specialized assay kits and consumables.

• •Covers reagents for immunoassays, molecular diagnostics, and microbiology testing used in detecting infectious diseases across the region
• •Serves hospitals, clinical laboratories, and point-of-care facilities throughout Middle East and Africa markets
• •Addresses high burden of infectious diseases including HIV, tuberculosis, hepatitis, and respiratory infections

The heavy burden of infectious and chronic diseases across the Middle East and Africa creates sustained demand for diagnostic testing and the reagents that power these assays. Government investments in diagnostic infrastructure, particularly in Gulf Cooperation Council countries, are expanding laboratory capacity and modernizing testing platforms. The shift toward molecular diagnostics and PCR technology is increasing demand for high-sensitivity reagent kits and nucleic acid amplification products.

• •High prevalence of infectious diseases driving continuous demand for diagnostic testing across healthcare facilities
• •Government initiatives and infrastructure investments expanding laboratory capacity in GCC and regional markets
• •Adoption of molecular diagnostics and PCR-based testing increasing requirements for specialized reagents and assay kits

The market encompasses several technology platforms, with molecular diagnostics and reagents representing the fastest-growing segment as laboratories adopt nucleic acid testing for its superior accuracy and speed. The United Arab Emirates leads regional demand with an infectious disease diagnostics market approaching $8.5 billion, supported by aggressive government spending on healthcare infrastructure and PCR testing capacity. Saudi Arabia emerges as the fastest-growing national market within the broader Middle East and Africa molecular diagnostics space, fueled by expansion of laboratory testing services and increased screening for bloodborne and respiratory infections.

• •Molecular diagnostics and reagents segment expanding at faster rates than traditional immunoassay platforms
• •UAE represents one of the largest national markets with significant government-funded diagnostic infrastructure expansion
• •Saudi Arabia identified as the fastest-growing market for molecular diagnostics in the region

What are the recent trends and outlook?

The market is trending toward point-of-care molecular testing and multiplex assay panels that enable simultaneous detection of multiple pathogens from a single sample. Laboratories are increasingly adopting integrated diagnostic platforms that combine reagents with automated sample processing to improve throughput and reduce human error. Over the coming years, the market will likely benefit from continued healthcare investment, regulatory harmonization efforts, and the growing preference for rapid, accurate molecular testing methods that can better manage infectious disease outbreaks.

• •Growing adoption of point-of-care molecular testing and multiplex panels for simultaneous pathogen detection
• •Shift toward integrated diagnostic platforms combining reagents with automated sample processing systems
• •Increasing emphasis on rapid, accurate molecular testing methods to improve infectious disease outbreak response